We are live on ! Find out more
YMAB

Y-mAbs Therapeutics
YMAB

Delisted

YMAB was delisted on the 15th of September, 2025.

Back to rankings

91 hedge funds and large institutions have $330M invested in Y-mAbs Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 34 increasing their positions, 26 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

43,000% more call options, than puts

Call options by funds: $2.59M | Put options by funds: $6K

63% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 8

31% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 26

24% more capital invested

Capital invested by funds: $266M → $330M (+$63.6M)

3% more funds holding

Funds holding: 88 → 91 (+3)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.25% less ownership

Funds ownership: 57.89% → 56.64% (-1.2%)

Holders
91
Holders Change
+3
Holders Change %
+3.41%
% of All Funds
1.53%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
13
Increased
34
Reduced
26
Closed
8
Calls
$2.59M
Puts
$6K
Net Calls
+$2.58M
Net Calls Change
-$97K

Top Buyers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
+$4.86M
2
PA
Perceptive Advisors
New York
+$2.47M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.58M
4
Invesco
Invesco
Georgia
+$1.17M
5
Millennium Management
Millennium Management
New York
+$954K

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$6.6M
2
Bank of America
Bank of America
North Carolina
-$3.85M
3
Deutsche Bank
Deutsche Bank
Germany
-$2.74M
4
Morgan Stanley
Morgan Stanley
New York
-$1.95M
5
AllianceBernstein
AllianceBernstein
Tennessee
-$1.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$45M +$363K +31,127 +1%
AllianceBernstein
2
AllianceBernstein
Tennessee
$42.6M -$1.79M -153,294 -5%
SI
3
Sofinnova Investments
California
$33.2M – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$29.8M +$6.8K +583 +0%
Vanguard Group
5
Vanguard Group
Pennsylvania
$29.2M +$1.58M +135,406 +8%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$28.3M -$469K -40,199 -2%
State Street
7
State Street
Massachusetts
$26.4M -$6.6M -565,640 -24%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$9.47M +$497K +42,639 +7%
MB
9
MPM BioImpact
Massachusetts
$6.71M – – –
Walleye Capital
10
Walleye Capital
New York
$6.3M +$4.86M +416,140 New
AG
11
Artal Group
Luxembourg
$6.05M – – –
Morgan Stanley
12
Morgan Stanley
New York
$5.66M -$1.95M -167,405 -31%
Northern Trust
13
Northern Trust
Illinois
$5.04M +$68.2K +5,845 +2%
Charles Schwab
14
Charles Schwab
California
$3.75M +$162K +13,852 +6%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$3.33M +$427K +36,599 +20%
PA
16
Perceptive Advisors
New York
$3.21M +$2.47M +212,018 New
MSKCC
17
Memorial Sloan Kettering Cancer Center
New York
$2.89M – – –
LOAMS
18
Lombard Odier Asset Management (Switzerland)
Switzerland
$2.74M -$476K -40,841 -18%
CS
19
Candriam SCA
Luxembourg
$2.61M – – –
Goldman Sachs
20
Goldman Sachs
New York
$2.3M +$299K +25,615 +20%
CAM
21
Cormorant Asset Management
Massachusetts
$2.27M – – –
Renaissance Technologies
22
Renaissance Technologies
New York
$2.27M +$686K +58,800 +65%
SCM
23
Soleus Capital Management
Connecticut
$2.06M -$1.2M -102,800 -43%
Invesco
24
Invesco
Georgia
$1.75M +$1.17M +100,158 +661%
N
25
Nuveen
North Carolina
$1.63M +$14.7K +1,256 +1%
1
2 3 4

YMAB Hedge Fund Activity: Q2 2022 in Review

91 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q2 2022, worth a combined $330M — up 24% from $266M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new YMAB positions and 8 closed out — a net gain of 5 holders — while 34 added to existing stakes and 26 trimmed.

The largest buyer was Walleye Capital, opening a new position worth an estimated $4.86M. The largest seller was State Street, cutting an estimated $6.6M.

  • 91 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q2 2022, up from 88 in Q1 2022.
  • Funds reported $330M of Y-mAbs Therapeutics stock for Q2 2022, up 24% quarter-over-quarter.
  • 13 funds opened new Y-mAbs Therapeutics positions in Q2 2022 and 8 closed out, a net change of +5 holders.
  • The largest Y-mAbs Therapeutics buyer in Q2 2022 was Walleye Capital, an estimated $4.86M added.
  • The largest Y-mAbs Therapeutics seller in Q2 2022 was State Street, an estimated $6.6M sold.

Based on aggregated 13F filings for Q2 2022.